Lakewood-Amedex Biotherapeutics Inc. (LABT) Ownership
LABT ownership summary
as of October 18, 2026- Institutions
- 6.0% of shares outstanding
- Insiders
- 39.47% of shares outstanding
- Shares outstanding
- 2.4M
- Float
- 848K shares available to trade
- Short interest
- 10.72% 131K shares short
- Days to cover
- 0.05 short interest up 146.8% vs prior month
- Institutions 6.02%
- Insiders 39.47%
- Other investors 54.51%
LABT top institutional holders
6 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Marex Group Ltd | 2.03% | 48K | $27,937 | +48,167 (0.0%) | June 30, 2026 |
| 2 | HRT FINANCIAL LLC | 1.89% | 45K | $25,974 | +44,782 (0.0%) | June 30, 2026 |
| 3 | UBS Group AG | 0.17% | 4,098 | $2,377 | +4,098 (0.0%) | June 30, 2026 |
| 4 | Tower Research Capital LLC | 0.03% | 624 | $362 | +624 (0.0%) | June 30, 2026 |
| 5 | Advisor Group Holdings, Inc. | 0.01% | 138 | $80 | +138 (0.0%) | June 30, 2026 |
| 6 | Ronald Blue Trust, Inc. | <0.01% | 11 | $6 | +11 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 6, 6 holders added 98K shares and 0 cut 0.
LABT top mutual fund and ETF holders
2 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index | 1.83% | 43K | $25,118 | +43,307 (0.0%) | August 31, 2026 |
| 2 | Fidelity Extended Market Index | 0.06% | 1,493 | $866 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns LABT
Institutional investors own 6.0% of Lakewood-Amedex Biotherapeutics's shares and insiders 39.47%. The largest holder is Marex Group Ltd with 2.03% of the shares (48K), as of June 30, 2026. Among the top 6 institutions, 6 added shares and 0 reduced their stake in the latest filings. Short interest is 10.72% of the float, or 0.05 days of average trading volume. The share count fell 86.3% since 2024.
Related: LABT analyst forecast, LABT key metrics. See the LABT stock overview for the latest quote and news.
LABT ownership FAQ
Who owns the most Lakewood-Amedex Biotherapeutics stock?
The largest shareholders of Lakewood-Amedex Biotherapeutics are Marex Group Ltd (2.03%), HRT FINANCIAL LLC (1.89%), UBS Group AG (0.17%), Tower Research Capital LLC (0.03%), Advisor Group Holdings, Inc. (0.01%).
What percentage of Lakewood-Amedex Biotherapeutics is owned by institutions?
Institutions hold 6.0% of Lakewood-Amedex Biotherapeutics's shares outstanding; insiders hold 39.47%.
Which funds own Lakewood-Amedex Biotherapeutics?
The largest fund holders of Lakewood-Amedex Biotherapeutics are Fidelity Nasdaq Composite Index (1.83%), Fidelity Extended Market Index (0.06%).
What is Lakewood-Amedex Biotherapeutics's short interest?
131K shares of Lakewood-Amedex Biotherapeutics were sold short, 10.72% of the float; at the average daily volume it would take 0.05 days to cover.
How many shares of Lakewood-Amedex Biotherapeutics are outstanding?
Lakewood-Amedex Biotherapeutics has 2.4M shares outstanding, of which 848K are in the public float.